Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin.
Seliger C, Meyer AL, Leidgens V, Rauer L, Moeckel S, Jachnik B, Proske J, Dettmer K, Rothhammer-Hampl T, Kaulen LD, Riemenschneider MJ, Oefner PJ, Kreutz M, Schmidt NO, Merrill M, Uhl M, Renner K, Vollmann-Zwerenz A, Proescholdt M, Hau P. Seliger C, et al. Among authors: uhl m. Int J Mol Sci. 2022 Oct 1;23(19):11629. doi: 10.3390/ijms231911629. Int J Mol Sci. 2022. PMID: 36232951 Free PMC article.
Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.
Seliger C, Meyer AL, Renner K, Leidgens V, Moeckel S, Jachnik B, Dettmer K, Tischler U, Gerthofer V, Rauer L, Uhl M, Proescholdt M, Bogdahn U, Riemenschneider MJ, Oefner PJ, Kreutz M, Vollmann-Zwerenz A, Hau P. Seliger C, et al. Among authors: uhl m. Cell Cycle. 2016 Jul 2;15(13):1755-66. doi: 10.1080/15384101.2016.1186316. Epub 2016 May 10. Cell Cycle. 2016. PMID: 27163626 Free PMC article.
Use of cardiac glycosides and risk of glioma.
Seliger C, Meier CR, Jick SS, Uhl M, Bogdahn U, Hau P, Leitzmann MF. Seliger C, et al. Among authors: uhl m. J Neurooncol. 2016 Apr;127(2):321-8. doi: 10.1007/s11060-015-2036-2. Epub 2015 Dec 31. J Neurooncol. 2016. PMID: 26721242
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Schäfer N, et al. Among authors: uhl m. Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204. Neuro Oncol. 2018. PMID: 29121274 Free PMC article. Clinical Trial.
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Weller J, et al. Among authors: uhl m. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2. Lancet Oncol. 2019. PMID: 31488360 Clinical Trial.
445 results